2024
ASO Visual Abstract: Clipping the Positive Lymph Node in Patients with Clinically Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial
Switalla K, Boughey J, Dimitroff K, Yau C, Ladores V, Yu H, Tchou J, Golshan M, Ahrendt G, Postlewait L, Piltin M, Reyna C, Matsen C, Tuttle T, Wallace A, Arciero C, Lee M, Tseng J, Son J, Rao R, Sauder C, Naik A, Howard-McNatt M, Lancaster R, Norwood P, Esserman L, Mukhtar R. ASO Visual Abstract: Clipping the Positive Lymph Node in Patients with Clinically Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial. Annals Of Surgical Oncology 2024, 1-2. DOI: 10.1245/s10434-024-15965-8.Peer-Reviewed Original Research
2021
119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial
Loibl S, Sikov W, Huober J, Rugo H, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo J, Metzger O, Dunbar M, Symmans W, Geyer C. 119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial. Annals Of Oncology 2021, 32: s408. DOI: 10.1016/j.annonc.2021.08.400.Peer-Reviewed Original ResearchASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)
Weiss A, Campbell J, Ballman K, Sikov W, Carey L, Hwang E, Poppe M, Partridge A, Ollila D, Golshan M. ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Annals Of Surgical Oncology 2021, 28: 436-437. DOI: 10.1245/s10434-021-10005-1.Peer-Reviewed Original Research
2019
Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.
Metzger Filho O, Stover D, Asad S, Ansell P, Watson M, Loibl S, Geyer C, O'Shaughnessy J, Untch M, Rugo H, Huober J, Golshan M, Sikov W, Von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Symmans W. Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study. Journal Of Clinical Oncology 2019, 37: 510-510. DOI: 10.1200/jco.2019.37.15_suppl.510.Peer-Reviewed Original ResearchPathologic complete responseNAC regimensNeoadjuvant chemotherapyPhase III studyT cell infiltrationClinico-pathologic variablesSignificant predictorsIII studyImmune signaturesComplete responseIndependent predictorsResearch biopsiesTNBC subtypesTotal macrophagesM2 macrophagesMultivariate analysisTNBCTumor proliferationImmunophenotypeTumorsBasal-likeRegimensChemotherapyCIBERSORTPAM50Magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer
Golshan M, Wong S, Loibl S, Huober J, O'Shaughnessy J, Rugo H, Wolmark N, McKee M, Maag D, Sullivan D, Metzger-Filho O, Von Minckwitz G, Geyer C, Sikov W, Untch M. Magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer. European Journal Of Surgical Oncology 2019, 45: e12-e13. DOI: 10.1016/j.ejso.2018.10.075.Peer-Reviewed Original Research
2013
Reducing breast cancer chemotherapy treatment delays by improving the transition from surgical to medical oncology.
Losk K, Kadish S, Golshan M, Lin N, Hirshfield-Bartek J, Cutone L, Bunnell C, Weingart S. Reducing breast cancer chemotherapy treatment delays by improving the transition from surgical to medical oncology. Journal Of Clinical Oncology 2013, 31: 51-51. DOI: 10.1200/jco.2013.31.31_suppl.51.Peer-Reviewed Original ResearchInitiation of chemotherapyBreast cancer patientsMedical oncologyOncology followDefinitive surgeryCancer patientsConsecutive breast cancer patientsChemotherapy treatment delaysAdverse clinical outcomesBreast cancer careTransitions of careProcess of careAdjuvant chemotherapyTimely chemotherapyMedical oncologistsClinical outcomesTreatment delayBreast surgeryCancer careInitial consultationBreast surgeonsCare coordinationChemotherapySurgeryMultidisciplinary team
2004
Prediction of breast cancer size by ultrasound, mammography and core biopsy
Golshan M, Fung B, Wiley E, Wolfman J, Rademaker A, Morrow M. Prediction of breast cancer size by ultrasound, mammography and core biopsy. The Breast 2004, 13: 265-271. PMID: 15325659, DOI: 10.1016/j.breast.2004.05.005.Peer-Reviewed Original Research